Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation-Reference-Cited by-同舟云学术

Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation

Published:2010-11 Issue:5 Volume:18 Page:423-435
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Liang Ke,Esteva Francisco J.,Albarracin Constance,Stemke-Hale Katherine,Lu Yang,Bianchini Giampaolo,Yang Ching-Yi,Li Yong,Li Xinqun,Chen Chun-Te,Mills Gordon B.,Hortobagyi Gabriel N.,Mendelsohn John,Hung Mien-Chie,Fan Zhen

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference34 articles.

1. Src family kinases and HER2 interactions in human breast cancer cell growth and survival;Belsches-Jablonski;Oncogene,2001

2. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer;Berns;Cancer Cell,2007

3. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials;Bohlius;Lancet,2009

4. Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein;Damen;Blood,1993

5. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor;Damen;Blood,1993

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer;Drug Resistance Updates;2024-03

2. AXL – a new player in resistance to HER2 blockade;Cancer Treatment Reviews;2023-12

3. The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study;Breast Cancer Research and Treatment;2023-11-08

4. Erythropoietin receptor is a risk factor for prognosis: A potential biomarker in lung adenocarcinoma;Pathology - Research and Practice;2023-11

5. Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers;International Immunopharmacology;2023-09